Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Repository for National Donor Program (NMDP) Research Blood Samples.

Hematologic

Hematologic
N/A
Kassim, Adetola
NMDPCTT0346

Hematologic Malignancy Tumor Bank

Multiple Cancer Types

Hematologic, Leukemia, Lymphoma
N/A
Seegmiller, Adam
VICCHEM1217

Optimization of Cancer Therapy Using Immune Effector Cells

Hematologic

Hematologic
N/A
Oluwole, Olalekan
VICCCTT1834

Noninterventional Epigenomic Mapping of CD34+ Cells From Healthy Participants and Patients with Myelofibrosis (MF) and Polycythemia Vera (PV)

Hematologic

Hematologic
N/A
Savona, Michael
VICCHEM18100

Efficacy and Safety of Concizumab Prophylaxis in Pts w/Haemophilia A or B without Inhibitors

Hematologic

Hematologic
III
Wheeler, Allison
VICCNCBH1996

Prospective Validation of a Venous Thrombosis Risk Assessment Model in Critically Ill Children from the CHAT Registry

Hematologic

Hematologic
N/A
Wheeler, Allison
VICCNCBH2010

Discovering Outcomes in Clonal Hematopoiesis: The Clonal Hematopoiesis and Inflammation in VasculaturE (CHIVE) Registry and Biorepository

Hematologic

Hematologic
N/A
Savona, Michael
VICCHEM20123


Ruxolitinib Phosphate in Treating Older Patients with Acute Myeloid Leukemia in First Complete Remission after Donor Stem Cell Transplant

Multiple Cancer Types

This phase II trial studies how well ruxolitinib phosphate works in treating older patients with acute myeloid leukemia in first complete remission after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Hematologic, Leukemia
II
Byrne, Michael
NCT03286530
VICCCTT1778

Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)

Hematologic

This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with SCD with strokes; and (2) adults with severe SCD.
Hematologic
II
Kassim, Adetola
NCT03263559
VICCNCCTT1759

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: